All News
Rheumatology Workforce: Is it a Women’s Issue?
I recently sat down with Dr. Daniel Battafarano, chair of the ACR’s Workforce Solutions Committee, to discuss workforce study findings, their impact on the next few years, and proposed interventions to address these issues.
Read Article
Rheumatologist - Work-Life Survey Results
During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
Read Article
Women are 80% of healthcare workforce; 97% of EU nurses & midwives are women- yet women earn 24% less than men & hold 25% of senior roles in the health sector. WHO officials call for equal pay/promotion, better work conditions &gender specific solutions https://t.co/ccuFnTmnvF https://t.co/V03RnXB1JE
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271 avail) of Adult Rheum fellow positions matched (only 4/127 programs did not fill their match). Pediatric Rheum 27/41 positions (62.8%)were filled (14/32 programs not filling). https://t.co/VECH6rMHBV https://t.co/MC1jhLCQBk
Links:
Dr. John Cush RheumNow ( View Tweet)
Gender Norms in Chronic Pain
Sensitive women and stoical men are the prevalent images of people in chronic pain. Unwarranted differences in medical treatment may result, as a University of Gothenburg doctoral thesis emphasizes.
https://t.co/HcCURc0fMz https://t.co/ZWNk5D3JvH
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch Dr. Alexis Ogdie discuss sex differences in axSpA, addressing disease susceptibility and outcomes, prevalence ratios, differences in PROs and the latest research.
https://t.co/ldQRGBX1g1 https://t.co/XVRZ3wjG7M
Links:
Dr. John Cush RheumNow ( View Tweet)
Our next Tuesday Night Rheumatology addresses Contract Negotiations, featuring Andrea Liberatore, JD, Gwenesta Melton, MD, and Kathryn Dao, MD.
Sign up to attend this and all of our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/ooO4ZcneLB https://t.co/eNUkqljtpj
Links:
Dr. John Cush RheumNow ( View Tweet)
Friday's podcast "You Can Have it All” is out now and available for download.
Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.
https://t.co/ugZNDqfvsB https://t.co/kNkVwIAlJ5
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 Doximity Physician salary survey shows that among the least paid specialties; Pediatric rheumatology was #3 at $226k and Adult Rheumatology was #20 at $299K https://t.co/HL7vReY6Vg https://t.co/LbWQ9IBUWr
Links:
Dr. John Cush RheumNow ( View Tweet)
Did you miss this week’s TNR? Check it now.
Straddling Career and Family
https://t.co/gFknaiJZBa https://t.co/K5VhxVeW1y
Links:
Dr. John Cush RheumNow ( View Tweet)
What Advocacy Taught Me About Leadership
https://t.co/biwd8ueSI0 https://t.co/ZDizyGHttO
Links:
Dr. John Cush RheumNow ( View Tweet)
British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline
BSR last published its guideline for SSc in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
https://t.co/s4AKdVS2H7 https://t.co/MmIGw2QLEn
Links:
Dr. John Cush RheumNow ( View Tweet)
Inflammasome inhibitors in development:
- RRx-001 in cancer, ALS, parkinsons
- OLT1177 in OA knee, gout, Schnitzlers
- DFV890 in CAPs, knee OA
- IZD174/334 in CAPS
- ZYIL1 CAPS
https://t.co/1oCmKIHchP https://t.co/Y8CBAx2T7w
Links:
Dr. John Cush RheumNow ( View Tweet)
New downlaod available: Gender Risk in Rheumatic Disease
https://t.co/5AQhSNzrvh https://t.co/wTGnCk7ctj
Links:
Dr. John Cush RheumNow ( View Tweet)
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
https://t.co/k4UZZtyvdf https://t.co/ZI3NMw7Iec
Links:
Dr. John Cush RheumNow ( View Tweet)
Paxlovid (Nirmatrelvir-Ritonavir) should be used w/in 5d of COVID Sxs onset. Drug interactions include: steroids, anticoagulants (Eliquis, Xarelto, warfarin), Flomax, Calcium channel blockers, benzodiazepines. https://t.co/FmjeWvWo58 https://t.co/BaKwun23pD
Links:
Dr. John Cush RheumNow ( View Tweet)
Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/OFb0vtndf1 https://t.co/14g2Fzeh2i
Links:
Dr. John Cush RheumNow ( View Tweet)
DESIR - early SpA Cohort study of 494 pts (half F); w/ 6 yrs F/U, Women had higher ASDAS-CRP & PtGA (P < 0.0001; vs men), yet CRP was similar and structural damage more frequent in men (P < 0.0001). https://t.co/cxehQuEOtu https://t.co/6PwtjEgLDD
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Changing the Conversation with Patients: Lupus
https://t.co/rFM2211Toq https://t.co/I9yWGMCH9B
Links:
Dr. John Cush RheumNow ( View Tweet)
AMA survey shows 94% MD report delays in Pt care assoc w/ prior authorization. MDs spend 2d/wk on PA &1/3 hire added staff for PA. 4/5 PAs result in abandoned Rx. CMC has a proposed rule to speed up PA approval. Congress needs to act on this PA problem! https://t.co/XNtlk5TzX5 https://t.co/QtzXQLyjWD
Links:
Dr. John Cush RheumNow ( View Tweet)